All AbMole products are for research use only, cannot be used for human consumption.
BV6 induces autoubiquitination and subsequent proteasomal degradation of cIAP1 and cIAP2, and greatly sensitizes cells to TNF-induced necrosis. BV6 significantly enhances the radiosensitization of HCC193 and H460 cells in vitro. BV6 sensitizes both cell lines to radiation (HCC193-DER = 1.38, p < 0.05 at 1 μM BV6; H460-DER = 1.42, p < 0.05 at 5 μM BV6), but a higher concentration of and longer incubation time with BV6 was necessary for H460 cells.
Int J Mol Sci. 2023 Jan 24;24(3):2320.
Reovirus Type 3 Dearing Variants Do Not Induce Necroptosis in RIPK3-Expressing Human Tumor Cell Lines
BV6 purchased from AbMole
Cancer Gene Ther. 2022 Jul 22.
Gastrointestinal cancer-associated fibroblasts expressing Junctional Adhesion Molecule-A are amenable to infection by oncolytic reovirus
BV6 purchased from AbMole
| Cell Experiment | |
|---|---|
| Cell lines | HCC193 and H460 cells |
| Preparation method | Using the CellTiter 96® Aqueous Non-Radioactive Cell Proliferation Assay kit to measure cell viability . Seeding 5000 cells/well into 96-well plates in triplicate. Following adhesion of cells to the wells, adding increasing concentrations of BV6 into different wells.Exposing control groups to the same concentration of DMSO. Addng the final concentrations of 333 μg/mL MTS and 25 μM PMS to each well 24 hours later. After two hours incubation at 37 °C in humidified 5% CO2, read plates at the absorbance of 490-nm on a microplate reader.Calculating relative cell viability of an individual sample by normalizing their absorbance to that of the corresponding control. Using Prism 5.01 to calculate IC50 values . For the TNFα neutralizing antibody assay, exposing cells to 1 and 5 μM BV6 with or without 10 μg/mL infliximab and the assay is performed 24 hours later. Read plates at the absorbance of 490-nm on a microplate reader |
| Concentrations | ~30 μM |
| Incubation time | ~48 hours |
| Animal Experiment | |
|---|---|
| Animal models | |
| Formulation | |
| Dosages | |
| Administration | |
| Molecular Weight | 1205.57 |
| Formula | C70H96N10O8 |
| CAS Number | 1001600-56-1 |
| Solubility (25°C) | DMSO >51 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related IAP Products |
|---|
| AT-406
Xevinapant (Debio1143,AT-406, SM-406) is a potentially first-in-class, highly potent oral antagonist of inhibitor of apoptosis protein (IAP), which not only promotes cancer cell death by inhibiting IAP, but also It can enhance the anti-tumor immune response by inhibiting IAP. |
| GDC-0152
GDC-0152 is a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins with potential antineoplastic activity. |
| Birinapant
Birinapant (TL32711) is a bivalent Smac analogue, which is a potent antagonist of XIAP and cIAP1 with Kd values of 45 nM and less than 1 nM, respectively. Birinapant (TL32711) induces autoubiquitination and proteasome degradation of cIAP1 and cIAP2 in intact cells, resulting in the formation of RIPK1: Caspase-8 complex, which activates and induces tumor cell death. |
| LCL161
LCL161 is an orally bioavailable SMAC mimetic, potently binds to and inhibits multiple IAPs (i.e. XIAP, c-IAP). LCL161 enhanced the proapoptotic effects of nilotinib and PKC412, against leukemic disease in vitro and potentiated the activity of both kinase inhibitors against leukemic disease in vivo. |
| Embelin
Embelin is a cell-permeable benzoquinone compound that exhibits antitumor properties. Specifically antagonizes XIAP-mediated inhibition of caspase-9 activation by directly targeting the Smac and caspase-9 binding domain BIR3 (IC50 = 4.1 uM in a competitive binding assay with Smac peptide). |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
